James Flinn

IP Director & Legal Counsel at Immutep

[CURE Today @cure_today]

First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell #LungCancer @Immutep https://t.co/mxcw2yhHZE

[Immutep @Immutep]

The first patient in our TACTI-004 lung cancer trial has been safely dosed in Australia, marking a significant milestone for the team at @Immutep!

Read the announcement: https://t.co/26viq9b6Kh

#efti #oncology #clinicaltrial #NSCLC

$IMM $IMMP

[Immutep @Immutep]

CEO Marc Voigt recently caught up with @sharecafetweets to discuss @Immutep's encouraging progress with #efti.

Listen here: https://t.co/MKwNpS03RB

#NSCLC #biotechnology #oncology

[Sharecafe @sharecafetweets]

Sip&Learn Webinar: Immutep's therapies move towards late-stage development
@Immutep $IMM $IMMP
https://t.co/pC7dh11jld

[Immutep @Immutep]

We’re pleased to provide our shareholders with a summary of a busy quarter in Q2 FY25, such as our transition to becoming a #PhaseIII biotech.

Read the update: https://t.co/HJJ1khtICS

#biotechnology #LAG3 #immunotherapy

[Seeking Alpha @SeekingAlpha]

$IMMP $PRRUF - Immutep Limited: Continuing To Make The Case For Eftilagimod. https://t.co/gEk2K83X3I #investing #trading #economy

[Immutep @Immutep]

ICYMI, catch Marc Voigt’s short presentation at @ausbiztv's Investor Connect event at the end of last year. Marc gives a quick snapshot of how @Immutep's lead product candidate fights cancer and how our late-stage clinical trials are tracking.

Watch: https://t.co/Xmz3uqx4yn

[Immutep @Immutep]

Marc Voigt, CEO of @Immutep, was delighted to join @ausbiztv's Investor Event to discuss its recent advancements in cancer treatment and its promising outlook following encouraging trial results.

Watch the short CEO interview: https://t.co/zMjP4enYSy

#biotechnology #LAG3

[Financial Review @FinancialReview]

Here are the under-the-radar stock picks that made the most money in 2024, with speculative ideas proving capable of huge returns. https://t.co/0b6Fo69rwO

[Immutep @Immutep]

ICYMI: Tune in to replay of fireside chat with Dr. Martin Forster of the @ucl Cancer Institute and @Immutep CEO Marc Voigt for an overview of recent data in 1L HNSCC patients with PD-L1 CPS <1 and insights into TACTI-004 Phase 3 in #lungcancer

Replay: https://t.co/U10AsbxJkM

[Multiple Sclerosis News Today @MSNewsToday]

Immutep said IMP761 was found safe in initial data from a Phase 1 trial, with no treatment-related adverse events reported. https://t.co/6OsqYLmyW6 #news

[Immutep @Immutep]

@Immutep is pleased to announce favourable initial safety data from the placebo-controlled, double-blind first-in-human Phase I study evaluating #IMP761.

Read more: https://t.co/dVxJi35rpy

#biotechnology #AutoimmuneDisease #LAG3 #immunotherapy

[Immutep @Immutep]

@Immutep in collab with @RossjohnLab first to publish structure of LAG-3/HLA-II complex & resolve how human LAG-3 binds to its main ligand, providing better foundation for development of blocking #LAG3 therapeutics incl its own small molecule program.

https://t.co/TXj2sMua2N

[Immutep @Immutep]

@Immutep is proud to report new positive results from efti in combination with KEYTRUDA® at #ESMOIO2024 in first line #HNSCC patients with PD-L1 expression below 1 (CPS <1). Data shows strong overall & progression-free survival and durability.

Read more: https://t.co/uoHKNC1NL2

[Finance News Network @Finnewsnetwork]

Immutep (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck.

https://t.co/SYeMpIzJNz

$IMM @Immutep

[Sharecafe @sharecafetweets]

Immutep (ASX:IMM) CEO and Executive Director Marc Voigt reflects on a year marked by promising clinical trial results and a landmark partnership with Merck.

https://t.co/VtLWiC7rXp

$IMM @Immutep

[Immutep @Immutep]

@Immutep is pleased to share an Investor Update discussing the upcoming TACTI-004 trial & becoming a Phase 3 biotech. The potential for efti combined with KEYTRUDA & chemo is to set a new standard-of-care in #NSCLC
Read more here: https://t.co/BLP5B247Z6
#LungCancerAwarenessMonth

[OncLive.com @OncLive]

Eftilagimod alpha plus pembrolizumb and chemotherapy generated favorable survival data in nonsquamous NSCLC. #lcsm #MedEd

Read here: https://t.co/UWwZHdkXmk

[Targeted Oncology @TargetedOnc]

In the phase 1 INSIGHT-003 trial, the combination of eftilagimod alpha, pembrolizumab, and chemotherapy showed promising results in terms of overall survival & progression-free survival in metastatic nonsquamous #NSCLC. #lcsm

https://t.co/JsXUjdl9IG

[Scrip, Citeline Commercial @PharmaScrip]

Immutep’s LAG-3 Adds To Keytruda In First-Line Lung Cancer https://t.co/5Zt9f3JZ6s #PharmaScrip